金域医学(603882) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was CNY 1,541,222,261.17, a decrease of 11.32% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2025 was CNY 5,197,288.53, an increase of 24.08% year-on-year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2025 was CNY 13,713,114.88, a significant increase of 264.54% compared to the previous year[9] - For the first nine months of 2025, the company's operating revenue was CNY 4,538,151,376.33, down 19.23% year-on-year[4] - The net profit attributable to shareholders for the first nine months of 2025 decreased by 184.84% year-on-year[9] - The net profit for the first three quarters of 2025 was a loss of CNY 88,794,076.93, compared to a profit of CNY 83,867,861.65 in the same period of 2024[24] - The company reported a net loss attributable to the parent company of CNY 87.75 million for the current period, compared to a profit of CNY 90.79 million in the previous period, indicating a significant decline[25] - Basic and diluted earnings per share for the current period were both CNY -0.17, compared to CNY 0.20 in the same period of the previous year[25] Cash Flow and Assets - The company reported a net cash flow from operating activities of CNY 671,907,894.48 for the first nine months, an increase of 115.41%[5] - The company achieved a significant improvement in accounts receivable recovery during the reporting period, with a net cash flow from operating activities of CNY 321 million in Q3 2025[10] - Cash inflow from operating activities totaled CNY 4.97 billion, while cash outflow was CNY 4.30 billion, resulting in a net cash flow from operating activities of CNY 671.91 million[28] - The company reported a significant increase in tax refunds received, amounting to CNY 80.13 million compared to CNY 3.26 million in the previous year[28] - The cash and cash equivalents as of September 30, 2025, amounted to approximately CNY 2.44 billion, compared to CNY 2.43 billion at the end of 2024[17] - Cash and cash equivalents at the end of the period increased to CNY 2.43 billion from CNY 1.94 billion at the end of the previous year, reflecting a net increase of CNY 8.93 million[29] - The company's total assets decreased to CNY 9,713,905,810.84 in 2025 from CNY 10,391,893,742.49 in 2024, reflecting a decline of 6.5%[19] - Total liabilities decreased to CNY 2,760,133,718.04 in 2025 from CNY 2,916,821,149.44 in 2024, a reduction of 5.4%[19] - The company's total equity decreased to CNY 6,953,772,092.80 in 2025 from CNY 7,475,072,593.05 in 2024, a decline of 7.0%[20] Revenue and Costs - Total operating revenue for the first three quarters of 2025 was CNY 4,538,151,376.33, a decrease of 19.2% compared to CNY 5,618,852,446.76 in the same period of 2024[23] - Total operating costs for the first three quarters of 2025 were CNY 4,282,602,888.45, down 16.3% from CNY 5,117,588,587.38 in 2024[23] - Total revenue for the first three quarters of 2025 was approximately CNY 4.81 billion, a decrease from CNY 5.48 billion in the same period of 2024, representing a decline of about 12.1%[27] Research and Development - Research and development expenses for the first three quarters of 2025 were CNY 243,155,334.32, down 19.6% from CNY 302,366,808.51 in 2024[24] Investments and Projects - The company signed 21 new medical community projects in the first three quarters of 2025, responding to national policies for quality medical resource allocation[10] - The company's revenue from its welfare system projects increased by 53.8% year-on-year as of the end of Q3 2025, expanding the number of projects to 69[11] - The "Xiao Yu Yi" smart report interpretation tool was accessed over 5.99 million times, with a monthly active user count of 140,000 as of Q3 2025[11] - The company has registered 6 specialized disease datasets on the Guangdong data intellectual property registration platform and listed 21 data products across various data exchanges[11] Investment Income - The company reported an investment income of CNY 3,657,566.25 in 2025, compared to a loss of CNY 5,122,643.98 in 2024[24] Inventory and Cash Management - The company’s cash and cash equivalents decreased to CNY 1,086,694,814.42 in 2025 from CNY 1,255,918,382.21 in 2024, a decrease of 13.5%[19] - The company’s inventory decreased slightly to CNY 190,612,298.75 in 2025 from CNY 198,315,250.59 in 2024, a decline of 4.0%[19] Financing Activities - Investment activities resulted in a net cash outflow of CNY 262.78 million, compared to a net outflow of CNY 361.42 million in the same period of 2024, showing an improvement[28] - Financing activities led to a net cash outflow of CNY 393.74 million, an improvement from a net outflow of CNY 463.11 million in the previous year[29] - The company received CNY 113.75 million from borrowings in the current period, a decrease from CNY 285.65 million in the same period of 2024[29]